DC Advisory advises Savanne Life Sciences on its seed investment in GEMMA Biotherapeutics

Background

• GEMMA Biotherapeutics (GEMMABio) is a therapeutics company led by gene therapy pioneer, Dr. Jim Wilson (MD, PhD), focused on advancing research and global access to life-changing advanced therapies for those living with rare diseases
  • Dr. Wilson is also the Chairperson of Franklin Biolabs, a contract research organization that provides a full range of services from discovery to clinical vector manufacturing to the global genetics medicines industry
• Savanne Life Sciences (Savanne) is well-versed in the field of medical research, with a new focus on investing in emerging biotechnology companies, having partnered with premier companies, universities and research institutions
• DC Advisory previously advised Savanne on its majority investment in Franklin Biolabs in September 2024

Process

• DC Advisory acted as the exclusive financial advisor to Savanne on its seed investment in GEMMABio
• DC Advisory provided financial advisory services to Savanne in connection with its evaluation of potential strategic growth opportunities, including supporting analyses and materials related to Savanne’s investment
  in GEMMABio

Outcome

• In December 2024, GEMMABio completed a $34 million seed funding round to accelerate its groundbreaking gene therapy initiatives
  • The seed round was co-led by Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital, with additional backing from Savanne
• This investment will fuel GEMMABio’s operational expansion and innovative gene therapy programs
• This transaction highlights DC Advisory’s strategic financial advisory expertise and its commitment to supporting long-term client relationships within the Healthcare / Life Sciences space